DURATION OF HUMAN PAPILLOMA VIRUS (HPV) TYPE-SPECIFIC ANTIBODY

这个子项目是利用资源的许多研究子项目之一 由NIH/NCRR资助的中心拨款提供。次级项目的主要支助 子项目的主要研究者可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 表示子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 使用QHPV - P1047的IMPAACT方案是一项封闭方案，正在研究QHPV在7至12岁的HIV感染女孩和男孩中的安全性和免疫原性。 本研究是一项安慰剂对照试验，比较了一个研究组（A组）与一个接受安慰剂的研究组（B组）中推荐的QHPV三次给药方案。在研究入组后96周，QHPV接受者（A组）接受第四剂QHPV，随后评价既往抗体应答的证据。同样在第96周，既往安慰剂接受者（B组）开始接受与A组相同的QHPV 3次给药方案。因此，两个不同的 目前已有队列可供今后评估。 总之，我们试图确定长期的持久性和动力学的疫苗诱导的HPV型特异性抗体和CMI反应的HIV感染的儿童，已经和正在免疫P1047。这些受试者是一个独特的群体， 让我们能够更好地解决这个临床问题。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. IMPAACT protocol that utilizes QHPV - P1047 is a closed protocol that is investigating the safety and immunogenicity of QHPV in HIV-infected girls and boys, age 7 to 12 years of age. This study was a placebo-controlled trial that compared a recommended three dose schedule of QHPV in one study arm (Arm A) with an arm that received placebo (Arm B). At 96 weeks after study entry the QHPV recipients (Arm A) received a fourth dose of QHPV and were subsequently evaluated for evidence of an anamnestic antibody response. Also at 96 weeks the previous placebo recipients (Arm B) began the same three dose schedule of QHPV that was administered in Arm A. Thus, two different cohorts are currently available for future evaluation. In summary, we seek to determine the long-term durability and kinetics of the vaccine-induced HPV-type-specific antibody and CMI responses in HIV-infected children that were, and are being, immunized in P1047. These subjects are a unique cohort that will allow us to approach this specific clinical issue.